Jiazhen Cui

1.5k total citations
39 papers, 423 citations indexed

About

Jiazhen Cui is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jiazhen Cui has authored 39 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Hematology. Recurrent topics in Jiazhen Cui's work include CAR-T cell therapy research (25 papers), Virus-based gene therapy research (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Jiazhen Cui is often cited by papers focused on CAR-T cell therapy research (25 papers), Virus-based gene therapy research (8 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Jiazhen Cui collaborates with scholars based in China, South Korea and United States. Jiazhen Cui's co-authors include He Huang, Yongxian Hu, Guoqing Wei, Shan Fu, Huijun Xu, Mingming Zhang, Linghui Zhou, Xiu‐Jian Wang, Alex H. Chang and Xinyi Teng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical and Biophysical Research Communications.

In The Last Decade

Jiazhen Cui

33 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiazhen Cui China 11 312 139 118 79 76 39 423
Ruimin Hong China 9 283 0.9× 127 0.9× 75 0.6× 60 0.8× 72 0.9× 29 355
Liora M. Schultz United States 10 347 1.1× 132 0.9× 202 1.7× 73 0.9× 77 1.0× 41 455
Rashmika Patel United States 8 339 1.1× 134 1.0× 118 1.0× 120 1.5× 77 1.0× 14 404
Yaohui Wu China 9 263 0.8× 120 0.9× 63 0.5× 68 0.9× 80 1.1× 26 379
Chunrong Tong China 11 337 1.1× 108 0.8× 113 1.0× 69 0.9× 86 1.1× 50 450
Vincent Allain France 9 231 0.7× 179 1.3× 81 0.7× 52 0.7× 99 1.3× 22 388
Xue Lin United States 6 441 1.4× 160 1.2× 138 1.2× 147 1.9× 120 1.6× 10 516
Sophia Stock Germany 9 337 1.1× 146 1.1× 121 1.0× 110 1.4× 97 1.3× 16 383
Xiaoqian Liang China 6 243 0.8× 117 0.8× 98 0.8× 54 0.7× 68 0.9× 8 334
Yvette Bernal United States 11 375 1.2× 142 1.0× 135 1.1× 67 0.8× 117 1.5× 22 459

Countries citing papers authored by Jiazhen Cui

Since Specialization
Citations

This map shows the geographic impact of Jiazhen Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiazhen Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiazhen Cui more than expected).

Fields of papers citing papers by Jiazhen Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiazhen Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiazhen Cui. The network helps show where Jiazhen Cui may publish in the future.

Co-authorship network of co-authors of Jiazhen Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Jiazhen Cui. A scholar is included among the top collaborators of Jiazhen Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiazhen Cui. Jiazhen Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Rongrong, Shan Fu, Yang D. Teng, et al.. (2025). Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. 13(3). e010687–e010687. 2 indexed citations
2.
Yang, Tingting, Yetian Dong, Mingming Zhang, et al.. (2025). Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia. Experimental Hematology and Oncology. 14(1). 2–2. 3 indexed citations
3.
4.
Chen, Zhili, Jiazhen Cui, Hao-Long Dong, et al.. (2024). Monitoring of Bacillus spore-forming dynamics through flow cytometry. Frontiers in Microbiology. 15. 1450913–1450913.
5.
Hu, Yongxian, Jiqin Zhang, Mingming Zhang, et al.. (2024). Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7031–7031. 1 indexed citations
6.
Huang, He, Yongxian Hu, Guoqing Wei, et al.. (2024). OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).. Journal of Clinical Oncology. 42(16_suppl). 7511–7511. 7 indexed citations
7.
Dong, Hao-Long, Zhili Chen, Jiazhen Cui, et al.. (2024). The Chimeric Chaoyang-Zika Vaccine Candidate Is Safe and Protective in Mice. Vaccines. 12(2). 215–215. 3 indexed citations
8.
Yang, Tingting, Yetian Dong, Mingming Zhang, et al.. (2024). Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 2818–2818. 1 indexed citations
9.
10.
Dong, Hao-Long, Qingyang Wang, Jiazhen Cui, et al.. (2023). Rapid Generation of Recombinant Flaviviruses Using Circular Polymerase Extension Reaction. Vaccines. 11(7). 1250–1250. 5 indexed citations
11.
Yi, Li, Yangyang Chen, Jiazhen Cui, et al.. (2023). Preparation and characterization of a neutralizing murine monoclonal antibody against tetanus toxin. Journal of Immunological Methods. 513. 113427–113427. 3 indexed citations
12.
Zhang, Mingming, Guoqing Wei, Linghui Zhou, et al.. (2023). GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology. 10(2). e107–e116. 91 indexed citations
13.
Fu, Shan, Qiqi Zhang, Ruirui Jing, et al.. (2023). HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transplantation. 58(6). 701–709. 10 indexed citations
14.
15.
Li, Yi, Fei Chen, Qingyang Wang, et al.. (2022). Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E. International Immunopharmacology. 113(Pt A). 109308–109308. 1 indexed citations
16.
Wei, Guoqing, Yanlei Zhang, Houli Zhao, et al.. (2021). CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research. 9(9). 1061–1070. 47 indexed citations
17.
Shao, Mi, Qin Yu, Xinyi Teng, et al.. (2021). CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplantation. 56(7). 1642–1650. 24 indexed citations
18.
Jin, Aiyun, Jingjing Feng, Guoqing Wei, et al.. (2020). CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. Bone Marrow Transplantation. 55(4). 717–721. 7 indexed citations
19.
Xu, Yinfeng, Xinping Zhao, Weihong Wen, et al.. (2020). A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity. Biochemical and Biophysical Research Communications. 534. 134–140. 17 indexed citations
20.
Liu, Huilin, et al.. (2015). Effect of intradialytic exercise in maintenance hemodialysis patients. 31(8). 583–588. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruimin Hong Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Rashmika Patel Breakdown of academic impact, for papers by Yaohui Wu Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Vincent Allain Breakdown of academic impact, for papers by Xue Lin Breakdown of academic impact, for papers by Sophia Stock Breakdown of academic impact, for papers by Xiaoqian Liang Breakdown of academic impact, for papers by Yvette Bernal
Rankless by CCL
2026